{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T12:00:37Z","timestamp":1774180837071,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.canlet.2020.09.013","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T11:34:56Z","timestamp":1600169696000},"page":"123-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft"],"prefix":"10.1016","volume":"495","author":[{"given":"Sisi","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guidong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fusheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2020.09.013_bib1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2020.09.013_bib2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2014.01.002","article-title":"Viruses for tumor therapy","volume":"15","author":"Bell","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.canlet.2020.09.013_bib3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.canlet.2007.02.002","article-title":"Oncolytic viruses in cancer therapy","volume":"254","author":"Vaha-Koskela","year":"2007","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2020.09.013_bib4","first-page":"4752","article-title":"Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1","volume":"55","author":"Yazaki","year":"1995","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.09.013_bib5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1126\/science.1851332","article-title":"Experimental therapy of human glioma by means of a genetically engineered virus mutant","volume":"252","author":"Martuza","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.canlet.2020.09.013_bib6","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1073\/pnas.92.5.1411","article-title":"Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma","volume":"92","author":"Chambers","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2020.09.013_bib7","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2020.09.013_bib8","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1096\/fasebj.13.11.1325","article-title":"Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207)","volume":"13","author":"Kooby","year":"1999","journal-title":"Faseb. J."},{"key":"10.1016\/j.canlet.2020.09.013_bib9","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2020.09.013_bib10","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"Kaufman","year":"2010","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.canlet.2020.09.013_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.canlet.2020.09.013_bib12","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.canlet.2020.09.013_bib13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0161-6420(90)32512-5","article-title":"Relative survival rates after alternative therapies for uveal melanoma","volume":"97","author":"Seddon","year":"1990","journal-title":"Ophthalmology"},{"key":"10.1016\/j.canlet.2020.09.013_bib14","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1001\/jamaophthalmol.2018.1813","article-title":"Continued poor survival in metastatic uveal melanoma: implications for molecular prognostication, surveillance imaging, adjuvant therapy, and clinical trials","volume":"136","author":"Johnson","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.canlet.2020.09.013_bib15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/hum.2018.107","article-title":"A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients","volume":"30","author":"Garcia","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.canlet.2020.09.013_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.10","article-title":"Designing herpes viruses as oncolytics","volume":"2","author":"Peters","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.canlet.2020.09.013_bib17","doi-asserted-by":"crossref","first-page":"11215","DOI":"10.1128\/JVI.74.23.11215-11221.2000","article-title":"Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein","volume":"74","author":"Poppers","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.canlet.2020.09.013_bib18","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1128\/JVI.72.3.2560-2563.1998","article-title":"Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP","volume":"72","author":"Tomazin","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.canlet.2020.09.013_bib19","first-page":"222","article-title":"Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma","volume":"4","author":"Miyatake","year":"1997","journal-title":"Canc. Gene Ther."},{"key":"10.1016\/j.canlet.2020.09.013_bib20","first-page":"5447","article-title":"Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil","volume":"61","author":"Nakamura","year":"2001","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.09.013_bib21","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nbt0598-444","article-title":"An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy","volume":"16","author":"Chase","year":"1998","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2020.09.013_bib22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.exer.2018.04.009","article-title":"Antitumor efficacy of VP22-CD\/5-FC suicide gene system mediated by lentivirus in a murine uveal melanoma model","volume":"172","author":"Liu","year":"2018","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.canlet.2020.09.013_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1755-148X.2012.00979.x","article-title":"The genetics of uveal melanoma: an emerging framework for targeted therapy","volume":"25","author":"Harbour","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.canlet.2020.09.013_bib24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nm.4098","article-title":"Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status","volume":"22","author":"Schoumacher","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2020.09.013_bib25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2004.06.006","article-title":"Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis","volume":"117","author":"Yang","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2020.09.013_bib26","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/1535-7163.MCT-19-0461","article-title":"Identification of ALDH1A3 as a viable therapeutic target in breast cancer metastasis-initiating cells","volume":"19","author":"Yamashita","year":"2020","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2020.09.013_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41416-019-0483-9","article-title":"ZEB1 and IL-6\/11-STAT3 signalling cooperate to define invasive potential of pancreatic cancer cells via differential regulation of the expression of S100 proteins","volume":"121","author":"Al-Ismaeel","year":"2019","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2020.09.013_bib28","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.cell.2014.07.032","article-title":"Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition","volume":"158","author":"Shaul","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2020.09.013_bib29","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0959-8049(00)00026-5","article-title":"Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed","volume":"36","author":"Peters","year":"2000","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.canlet.2020.09.013_bib30","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-13-2613","article-title":"Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal","volume":"20","author":"Li","year":"2014","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.09.013_bib31","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1172\/JCI122287","article-title":"Oncolytic viruses: overcoming translational challenges","volume":"130","author":"Martinez-Quintanilla","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2020.09.013_bib32","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/bjophthalmol-2011-301470","article-title":"Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines","volume":"96","author":"Huang","year":"2012","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.canlet.2020.09.013_bib33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrc1098","article-title":"The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited","volume":"3","author":"Fidler","year":"2003","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.09.013_bib34","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1158\/0008-5472.CAN-05-0616","article-title":"Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition?","volume":"65","author":"Thompson","year":"2005","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.09.013_bib35","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/nm.3336","article-title":"The epigenetics of epithelial-mesenchymal plasticity in cancer","volume":"19","author":"Tam","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2020.09.013_bib36","first-page":"999","article-title":"Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen","volume":"7","author":"Grem","year":"2001","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.09.013_bib37","first-page":"2006","article-title":"Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil","volume":"5","author":"Johnson","year":"1999","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.09.013_bib38","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.7150\/thno.14158","article-title":"Dihydropyrimidine dehydrogenase is a prognostic marker for mesenchymal stem cell-mediated cytosine deaminase gene and 5-fluorocytosine prodrug therapy for the treatment of recurrent gliomas","volume":"6","author":"Chung","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2020.09.013_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","article-title":"Clinical pharmacology of 5-fluorouracil","volume":"16","author":"Diasio","year":"1989","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.canlet.2020.09.013_bib40","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.09.013_bib41","article-title":"Suicide gene therapy for cancer - current strategies","volume":"4","author":"Zarogoulidis","year":"2013","journal-title":"J. Genet. Syndr. Gene Ther."},{"key":"10.1016\/j.canlet.2020.09.013_bib42","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2020.09.013_bib43","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1073\/pnas.91.17.8302","article-title":"Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase","volume":"91","author":"Huber","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2020.09.013_bib44","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3390\/v1030737","article-title":"Activation and evasion of innate antiviral immunity by herpes simplex virus","volume":"1","author":"Melchjorsen","year":"2009","journal-title":"Viruses"},{"key":"10.1016\/j.canlet.2020.09.013_bib45","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.1128\/JVI.72.11.8620-8626.1998","article-title":"The herpes simplex virus US11 protein effectively compensates for the gamma 1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2","volume":"72","author":"Cassady","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.canlet.2020.09.013_bib46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/glia.20450","article-title":"Distinct roles of protein kinase R and toll-like receptor 3 in the activation of astrocytes by viral stimuli","volume":"55","author":"Carpentier","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.canlet.2020.09.013_bib47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.canlet.2020.05.035","article-title":"STAT3: A key signaling molecule for converting cold to hot tumors","volume":"489","author":"Hu","year":"2020","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2020.09.013_bib48","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1172\/JCI34237","article-title":"IL-6 involvement in epithelial cancers","volume":"117","author":"Schafer","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2020.09.013_bib49","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.09.013_bib50","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1038\/onc.2009.180","article-title":"Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells","volume":"28","author":"Sullivan","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.09.013_bib51","doi-asserted-by":"crossref","first-page":"14665","DOI":"10.1074\/jbc.M707429200","article-title":"Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function","volume":"283","author":"Cheng","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2020.09.013_bib52","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.onc.1207003","article-title":"Stat3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89","volume":"23","author":"Wu","year":"2004","journal-title":"Oncogene"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520304754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520304754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:51:42Z","timestamp":1759593102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383520304754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":52,"alternative-id":["S0304383520304754"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2020.09.013","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2020.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}